Skip to content Skip to sidebar Skip to footer
Wall Street illustration with a red arrow showing the Dow falling and a blue arrow showing the Nasdaq rising ahead of Anthropic’s IPO.

U.S. stocks closed mixed Wednesday, November 18, 2026. The Dow Jones Industrial Average fell 561.25 points, or 1.11%, to 50,198.17, and the S&P 500 lost 0.23% to extend its losing streak to five sessions. The Nasdaq Composite gained 0.42%, and the Russell 2000 rose 0.52%. Nvidia (NVDA) reversed its initial post-earnings gains and closed down 2.89%, even as Anthropic’s pending initial public offering kept attention on demand for artificial intelligence stocks. The economic reports told two different stories. Federal Reserve minutes showed that nearly all policymakers saw further rate increases as likely under their baseline outlook, while October building permits fell 7.4% despite a rebound in housing starts. The 10-year Treasury yield eased to 5.07% in the closing snapshot, but the Fed minutes made clear that October’s decision to hold rates steady was not a signal that its tightening cycle was over.

November 18, 2026 market close: Major U.S. indexes

IndexClosing levelPoint changeDaily change
S&P 5007,323.63-16.90-0.23%
Dow Jones Industrial Average50,198.17-561.25-1.11%
Nasdaq Composite24,429.88+101.50+0.42%
Russell 20002,715.92+14.05+0.52%

The Nasdaq Composite and the small-cap Russell 2000 both finished higher, so the Dow’s 561-point decline did not reflect a uniform selloff.

Nvidia falls after earnings as Anthropic IPO pricing approaches

Nvidia (NVDA) ended at $150.96, down $4.50, after initially rising in response to its Tuesday earnings release. Fiscal third-quarter revenue grew 103% year over year, but the early gains did not hold. China remains a separate question from overall chip demand: interim CEO Colette Kress said the company recorded $2.4 billion in quarterly Hopper chip sales to China, halted those shipments, and was projecting no revenue from them going forward. The close showed that strong reported growth was not enough to lift the shares on Wednesday. Anthropic, the company behind Claude, was expected to price its IPO Wednesday evening and begin trading Thursday, November 19, under the proposed ticker ANT. The preliminary offering covered 825 million shares at $70 to $78 apiece, equivalent to $57.75 billion to $64.35 billion before a separate $26 billion private placement. Bloomberg reported that the offering could price above the marketed range. Those figures describe the proposed deal, not a confirmed final price. Thursday’s opening trade will provide a separate measure of what buyers are willing to pay once the shares are publicly available. The offering also puts early private-market valuations in perspective. A reported multibillion-dollar estimate for the Anthropic stake held by Ashton Kutcher’s Sound Ventures represents the value of the firm’s position on paper, not personal proceeds for Kutcher. The distinction matters when headline valuations are based on an offering that has not yet priced. Outside technology, Target (TGT) reported sales of $27.1 billion, up 7.1% from a year earlier, and comparable sales growth of 5.6%. Reported diluted earnings were $2.65 per share, including a $0.50 benefit from tariff refunds. The comparable sales figure gives a clearer view of underlying retail demand than the headline earnings increase alone.

Macroeconomic report: Fed minutes point to further hikes as housing permits fall

The Federal Open Market Committee voted 10–2 at its October 27–28 meeting to keep the federal funds target range at 3.75% to 4.00%. The minutes, released Wednesday, showed that nearly all participants judged further increases would likely be appropriate if inflation and the labor market evolved as expected. Fed Governor Lisa Cook and Cleveland Fed President Beth Hammack favored a quarter-point increase at the October meeting. The minutes describe the debate behind that decision; they do not announce a new rate move. October’s housing report was stronger on current construction than on planned projects. Housing starts rose 9.9% to a seasonally adjusted annual rate of 1.309 million, but that monthly gain was within the survey’s margin of error. Building permits fell 7.4% to a 1.295 million annual rate, and single-family permits dropped 8.7% to 772,000. Starts count homes that broke ground; permits show how many units were authorized for construction. That makes the permit decline a reason to be cautious about reading one month’s rise in starts as a sustained recovery. The day’s key macro contrast was that the 10-year Treasury yield fell even as the minutes pointed to the possibility of further rate hikes. The Fed sets a target for overnight rates, not the 10-year yield. Lower oil prices accompanied the bond rally on Wednesday, but one session of lower yields does not settle the inflation outlook or rule out another Fed increase.

Treasury yields, oil, gold, Bitcoin and volatility

MarketEnd-of-day snapshotDaily move
10-year U.S. Treasury yield5.07%About -4 basis points
Cboe Volatility Index (VIX)24.49-3.81%
December 2026 crude oil futures$81.85-3.31%
Gold$3,731.50-3.43%
Bitcoin$62,446.06-2.84%

What to watch Thursday, November 19

The clearest test for the AI trade will be where Anthropic opens relative to its final offering price. Wednesday’s session already showed why the distinction matters: Nvidia (NVDA) sold off after strong earnings, while the Nasdaq Composite still finished higher. The next question is whether Anthropic’s debut lifts other AI shares or whether demand remains concentrated in the new listing. On the macro calendar, the Census Bureau is scheduled to publish its advance third-quarter services report at 10 a.m. Eastern.

Updates From the VP Watchlist

Amwell® (NYSE: AMWL)

Amwell® (NYSE: AMWL), a leading provider of technology-enabled care, closed at $11.03. Amwell reported after the close Nov. 3 the company’s Third Quarter 2026 Highlights: Recorded Total Revenue of $49.0 million, exceeding the previously provided financial guidance range for Q3, Achieved subscription revenue of $23.9 million, Recorded Amwell Medical Group (“AMG”) visit revenue of $23.7 million, Reported gross margin of 53%, Net loss was ($11.0) million, compared to ($9.6) million in the second quarter of 2026, Adjusted EBITDA of ($3.6) million compared to ($1.2) million in the second quarter of 2026, & Total visits on the platform were 0.8 million. Financial Outlook: The Company is raising its 2026 revenue outlook, and adjusted EBITDA outlook, and reaffirming its AMG visit guidance., Revenue in the range of $204 million to $206 million increased from $200 million to $205 million. AMG visits between 1.32 million and 1.37 million Adjusted EBITDA in the range between ($8) million to ($7) million increased from ($9) million to ($7) million.

The Company also provided financial guidance for Q4 2026 Revenue and adjusted EBITDA:

  • Q4 revenue in the range of $48 million to $50 million
  • Q4 adjusted EBITDA expected to in the range of $0 million to $1 million.

The Company also reiterated its objective to achieve positive cash flow from operations in the fourth quarter of 2026.

Serina Therapeutics (NYSE: SER)

Serina Theraeuptics (NYSE: SER, $1.35) is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. Serina’s POZ PlatformTM provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). Serina is headquartered in Huntsville, Alabama on the campus of the HudsonAlpha Institute of Biotechnology.

On Thursday, November 12, Serina reported its financial results for the third quarter ended September 30, 2026, along with key business updates. Steve Ledger, Chief Executive Officer of Serina stated, “We are excited about the achievement of important clinical milestones for SER-252 in Parkinson’s disease, advancing from the initial evaluation of our lowest-dose cohort into the next stage of dose escalation. Importantly, the blinded pharmacokinetic observations from Cohort 1 showed the sustained drug exposure SER-252 was designed to achieve, and the independent Safety Monitoring Committee recommended proceeding with continued development. Dosing in Cohort 2 is currently underway and focuses on demonstrating SER-252’s potential as a differentiated treatment option for patients with advanced Parkinson’s disease to improve the significant challenge of consistent symptom control.”

On Thursday, September 24, 2026, Serina CEO Steve Ledger discussed discuss Serina’s programs’ progress during Tribe Public’s “A New Approach to Advanced Parkinson’s Disease: Serina Discusses SER-252’s Clinical Progress”webinar, followed by a live Q&A. You may view it below.

Eupraxia Pharmaceuticals Inc. (EPRX)

Eupraxia Pharmaceuticals Inc. (EPRX, $6.21), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today, ( Nov. 10), announced its financial results for the third quarter of 2026. Dr. James A. Helliwell, Chief Executive Officer of Eupraxia stated, “We remain on track to report interim results from the Phase 2b portion of the RESOLVE trial in December, and were pleased to announce in mid-October that we had reached our target enrollment of 120 patients. We are very encouraged by the Phase 1b/2a data from the open-label portion of the RESOLVE trial that was reported this quarter, which includes 36- and 52-week data from our highest dosing cohorts. We believe this data provides further evidence of the observed durable treatment effects of EP-104GI in EoE patients, seen in previous cohorts. In total, we have observed 64% of patients remaining in clinical remission over this 52-week period in addition to clinically meaningful histologic improvements. With cash runway into the second half of 2028, we believe we remain well funded to execute on our upcoming milestones for our EoE program.”

EPRX gained a significant new Wall Street endorsement Monday as RBC Capital Markets initiated coverage with an Outperform rating, a Speculative Risk designation and a $14 price target. The research makes a bullish case for EP-104GI, the company’s investigational treatment for eosinophilic esophagitis, ahead of an expected December clinical readout. Against the $6.89 reference price in RBC’s report, the target implies approximately 103% upside, not a forecast of where shares must trade. The attraction is unusually straightforward for biotechnology: take a familiar anti-inflammatory medicine, deliver it precisely into diseased tissue and attempt to make its benefits last long enough to change the treatment routine. If that approach succeeds, Eupraxia would offer more than another prescription for a chronic disease. It could offer a different calendar. RBC analyst Douglas Miehm’s November 9 initiation argues that EP-104GI could occupy a differentiated position in eosinophilic esophagitis, commonly called EoE, through localized delivery and the potential for once-yearly administration. The next major test is whether encouraging early results translate into convincing evidence against a vehicle control in the Phase 2b RESOLVE study.

EPRX announced (Oct. 15) that the ongoing RESOLVE study evaluating the safety and efficacy of EP-104GI for the treatment of Eosinophilic Esophagitis (“EoE”) has reached its enrollment target. “This is a significant milestone for the RESOLVE trial and the development of EP-104GI as a potential treatment option in EoE” said Dr. James Helliwell, Chief Executive Officer of Eupraxia. “We look forward to our interim analysis in December where we will be reporting on symptoms, histologic findings and safety in the first 60 patients in Phase 2b to reach 6 months. Data will also be available on the patients at 3, 9- and 12-month timepoints giving a fulsome interim look at the RESOLVE Trial”.

Modular Medical, Inc. (NASDAQ: MODD)

Modular Medical, Inc. (NASDAQ: MODD, $1.82, +1.11%), a commercial-stage medical device company preparing for the full commercial launch of its next-generation Pivot™ tubeless patch pump, is pursuing a different proposition: make insulin delivery less demanding for the people who must manage it every day. New patient research announced November 9 gives that strategy a persuasive commercial foundation. In a three-phase study conducted with Thrivable involving more than 540 people with Type 1 or Type 2 diabetes, approximately nine out of 10 surveyed multiple daily injection users said they would consider a simpler insulin delivery option. In the final-phase survey of 303 participants, 48.5% expressed strong interest in the company’s Pivot tubeless patch pump. The distinction matters. General enthusiasm for something easier is not the same as product-specific interest, and neither is a prescription. Still, the findings suggest Modular Medical is addressing a recognizable problem rather than inventing one for the benefit of a presentation deck. For many following MODD, the emerging opportunity centers on one word: simplicity. The company has already moved beyond the purely developmental stage. Its annual report documents U.S. Food and Drug Administration clearance for Pivot in April 2026, followed by commercial availability and initial patient shipments in June. The question now is whether a differentiated product, improving access and more focused patient education can turn that regulatory foundation into a repeatable commercial business.

MODD announced (Oct. 27) that it has received a positive decision from its notified body regarding certification of its quality management system under ISO 13485:2016. The notified body is designated under the European Union Medical Device Regulation (“MDR”).

MODD CEO, Jeb Besser, co-hosted a Tribe Public’s CEO Presentation and Q&A Webinar Event titled “The Road To Revenue: Modular Medical’s Strategy For Launching Pivot,” that was held Friday, September 4, 2026.. You may watch the event video below now if you missed it below now.

Alphabet (NASDAQ: GOOGL $282.44, +.80%)

Alphabet (NASDAQ: GOOGL, GOOG) is confronting an expensive paradox: Artificial intelligence is bringing more activity to Google while making the economics of that activity harder to predict. Yet the latest results offer a more constructive interpretation than a simple obituary for search. Third-quarter revenue increased 25% to $127.6 billion. Operating income climbed 30% to $40.6 billion. Google Cloud revenue more than doubled. Those are unusual credentials for a company supposedly being escorted toward technological irrelevance. At the close on Thursday, Alphabet shares traded at $283.82, following a 12.64% decline, many are clearly demanding more proof and fewer architectural renderings of future data centers. That skepticism is understandable. But the opportunity lies in distinguishing a difficult transition in monetization from a collapse in demand. Google’s problem is not that people have stopped asking questions. According to management, its year-over-year search-query growth reached its highest rate in five years during the third quarter. The more consequential question is how quickly Google can turn its expanding AI audience into attractive, durable cash flow. Wall Street has little patience for a renovation when the contractor’s estimate begins with a trillion.

Space Exploration Technologies Corp. (SPCX, $143.50, +1.27%)

SpaceX-related coverage is orbiting three themes: a possible combination with Tesla, an expanding AI infrastructure footprint, and robust Starlink demand, because apparently conquering one industry at a time is inefficient. Reported third-quarter revenue totaled $14.6 billion, while management projected first-quarter 2027 revenue of $33 billion–$37 billion, a range with little apparent interest in remaining earthbound.

The Sources

  1. [November 18 market updates and Target earnings coverage][finance.yahoo]
  2. [November 17 futures and Nvidia earnings reaction][cnbc]
  3. [Anthropic offering size and pricing coverage][cnbc]
  4. [Anthropic preliminary IPO range and proposed ticker][finance.yahoo]
  5. [Nvidia closing quote and China shipment coverage][finance.yahoo]
  6. [Sound Ventures and its Anthropic stake][finance.yahoo]
  7. [Bloomberg market wrap: November 18 closing session][swissinfo]
  8. [Bloomberg: Anthropic IPO terms and private placement][mercury.bloomberg]
  9. [Bloomberg: November 18 morning market reaction][bloomberg]
  10. [Federal Reserve: October 27–28 FOMC meeting minutes][federalreserve]
  11. [U.S. Census Bureau and HUD: October 2026 new residential construction report][census]
  12. [U.S. Census Bureau: New residential construction definitions and data][census]
  13. [U.S. Census Bureau: 2026 economic indicator release schedule][census]
Disclosure: This article is for informational purposes only and should not be construed as investment advice, a recommendation, or an offer to buy or sell any security. Market data are subject to revision, and investors should conduct independent due diligence before making investment decisions. Investments may involve substantial risk, including the potential loss of the entire investment. Investors should conduct independent due diligence and consider their individual objectives and risk tolerance. See The Complete Disclosure via this link & at the top of the page.